Hani Gabra

Hani Gabra

Imperial College London

H-index: 76

Europe-United Kingdom

About Hani Gabra

Hani Gabra, With an exceptional h-index of 76 and a recent h-index of 56 (since 2020), a distinguished researcher at Imperial College London, specializes in the field of Tumour Suppressor Genes, Gastrointestinal Cancer, Gynaecological Cancer, Clinical Informatics, OMICS.

His recent articles reflect a diverse array of research interests and contributions to the field:

Oncolytic Vaccinia Virus Carrying OPCML Tumor Suppressor is active in Epithelial Ovarian Cancer

Cancer therapeutic methods utilizing OPCML fragment

1h-pyrazolo [3, 4-d] pyrimidine compounds useful for the treatment of platinum-resistant cancer

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian …

Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian …

The genomic landscape of recurrent ovarian high grade serous carcinoma: the BriTROC-1 study

rOPCML-Fc as a potential tumor suppressive therapeutic agent for ovarian cancer

Hani Gabra Information

University

Position

___

Citations(all)

48015

Citations(since 2020)

35137

Cited By

26598

hIndex(all)

76

hIndex(since 2020)

56

i10Index(all)

172

i10Index(since 2020)

131

Email

University Profile Page

Google Scholar

Hani Gabra Skills & Research Interests

Tumour Suppressor Genes

Gastrointestinal Cancer

Gynaecological Cancer

Clinical Informatics

OMICS

Top articles of Hani Gabra

Oncolytic Vaccinia Virus Carrying OPCML Tumor Suppressor is active in Epithelial Ovarian Cancer

Cancer Research

2024/3/22

Cancer therapeutic methods utilizing OPCML fragment

2024/1/2

1h-pyrazolo [3, 4-d] pyrimidine compounds useful for the treatment of platinum-resistant cancer

2023/3/2

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

Gynecologic oncology

2023/3/1

Hani Gabra
Hani Gabra

H-Index: 54

Yan Jia
Yan Jia

H-Index: 5

ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian …

Annals of Surgical Oncology

2023

Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian …

Annals of Surgical Oncology

2023/1

The genomic landscape of recurrent ovarian high grade serous carcinoma: the BriTROC-1 study

medRxiv

2022/10/25

rOPCML-Fc as a potential tumor suppressive therapeutic agent for ovarian cancer

European Journal of Cancer

2022/10/1

AXL inhibition enhances Type 1 interferon (IFN) response and potentiates chemo-immunotherapy

Cancer Research

2022/6/15

Hani Gabra
Hani Gabra

H-Index: 54

AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells

Cell Reports Medicine

2022/3/15

Trametinib versus standard of care in patients with recurrent\ud low-grade serous ovarian cancer (GOG 281/LOGS):\ud an international, randomised, open-label, multicentre,\ud …

2022/2/5

OA01. 07 a phase II study of the oral selective Axl inhibitor bemcentinib with pembrolizumab in patients with advanced NSCLC

Journal of Thoracic Oncology

2021/3/1

Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers

2021/2

Jane Antony
Jane Antony

H-Index: 7

Hani Gabra
Hani Gabra

H-Index: 54

Targeting the receptor AXL by bemcentinib prevents SARS-CoV-2 infection

Topics in Antiviral Medicine

2021

Bemcentinib (oral AXL inhibitor) in combination with low-dose cytarabine is well tolerated and efficacious in older relapsed AML patients. updates from the ongoing phase II …

Blood

2021/11/23

Grerk Sutamtewagul
Grerk Sutamtewagul

H-Index: 6

Hani Gabra
Hani Gabra

H-Index: 54

602 AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells

2021/11/1

Effects of obesity and post-bariatric surgery weight loss on the vaginal microbiota

2021/10/16

A novel application of calcium electroporation to cutaneous manifestations of gynaecological cancer

Eur. J. Gynaecol. Oncol

2021/8/15

A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus …

Journal of Neurodevelopmental Disorders

2022/12

See List of Professors in Hani Gabra University(Imperial College London)